非苯二氮卓类安眠药扎来普龙治疗失眠症的临床前研究进展

B. Beer, D. E. Clody, R. Mangano, M. Levner, P. Mayer, J. E. Barrett
{"title":"非苯二氮卓类安眠药扎来普龙治疗失眠症的临床前研究进展","authors":"B. Beer,&nbsp;D. E. Clody,&nbsp;R. Mangano,&nbsp;M. Levner,&nbsp;P. Mayer,&nbsp;J. E. Barrett","doi":"10.1111/j.1527-3458.1997.tb00324.x","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Zaleplon (N-[3-(3-cyanopyrazolo[l,5-a]pyrimidin-7-y l)phenyl)]-N-ethylacetamide) is a non-benzodiazepine sedative-hypnotic with benzodiazepine-like sedative effects, but with less apparent liability for accompanying undesirable side effects. Zaleplon displaces [<sup>3</sup>H]flunitrazepam from rat cortical membranes with an IC<sub>50</sub> value of 200 nM and enhances t-butylbicyclophosphorothionate [<sup>35</sup>S]TBPS binding by 73%, suggesting pharmacological activity mediated by the GABA<sub>A</sub> benzodiazepine receptor complex. In various preclinical procedures such as motor activity, muscle relaxation, EEG, anticonvulsant activity, and vigilance, zaleplon produced effects similar to those of other sedative-hypnotic compounds such as triazolam and flurazepam; furthermore, these effects, when evaluated, were reversed by the benzodiazepine receptor antagonist flumazenil. Zaleplon increased punished (conflict) responding in squirrel monkeys and rats and these effects were also antagonized by flumazenil. When established as a discriminative stimulus in rats at 3.0mg/kg i.p., zaleplon showed a dose-related increase in drug-appropriate responding up to the training dose and a correlated decrease in response rate. Triazolam (0.1 to 1.0 mg/kg), the benzodiazepine partial agonist Ro 17-1812 (0.3 to 3.0mg/kg), and the triazolopyridine CL 218,872 (1.0 to 3.0 mg/kg) substituted consistently for zaleplon in all rats, whereas the imidazo-pyridines zolpidem (3.0 to 10 mg/kg) and alpidem (10 to 30 mg/kg), the benzodiazepine partial agonist bretazenil (0.03 to 10 mg/kg) and the novel putative anxio-lytic CL 273,547 (10 to 56 mg/kg) did not result in consistent drug-appropriate responding in all rats. These results suggest that the effects of zaleplon are similar in many respects to other compounds acting at the benzodiazepine receptor complex but differ as well from both benzodiazepine and non- benzodiazepine drugs. This profile of activity, coupled with additional information in ancillary procedures, yields a pre-clinical profile of a short-acting sedative-hypnotic non-benzodiazepine that is currently in Phase III development for the treatment of sleep disturbances.</p>\n </div>","PeriodicalId":94307,"journal":{"name":"CNS drug reviews","volume":"3 3","pages":"207-224"},"PeriodicalIF":0.0000,"publicationDate":"2006-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1527-3458.1997.tb00324.x","citationCount":"41","resultStr":"{\"title\":\"A Review of the Preclinical Development of Zaleplon, a Novel Non-Benzodiazepine Hypnotic for the Treatment of Insomnia\",\"authors\":\"B. Beer,&nbsp;D. E. Clody,&nbsp;R. Mangano,&nbsp;M. Levner,&nbsp;P. Mayer,&nbsp;J. E. Barrett\",\"doi\":\"10.1111/j.1527-3458.1997.tb00324.x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <p>Zaleplon (N-[3-(3-cyanopyrazolo[l,5-a]pyrimidin-7-y l)phenyl)]-N-ethylacetamide) is a non-benzodiazepine sedative-hypnotic with benzodiazepine-like sedative effects, but with less apparent liability for accompanying undesirable side effects. Zaleplon displaces [<sup>3</sup>H]flunitrazepam from rat cortical membranes with an IC<sub>50</sub> value of 200 nM and enhances t-butylbicyclophosphorothionate [<sup>35</sup>S]TBPS binding by 73%, suggesting pharmacological activity mediated by the GABA<sub>A</sub> benzodiazepine receptor complex. In various preclinical procedures such as motor activity, muscle relaxation, EEG, anticonvulsant activity, and vigilance, zaleplon produced effects similar to those of other sedative-hypnotic compounds such as triazolam and flurazepam; furthermore, these effects, when evaluated, were reversed by the benzodiazepine receptor antagonist flumazenil. Zaleplon increased punished (conflict) responding in squirrel monkeys and rats and these effects were also antagonized by flumazenil. When established as a discriminative stimulus in rats at 3.0mg/kg i.p., zaleplon showed a dose-related increase in drug-appropriate responding up to the training dose and a correlated decrease in response rate. Triazolam (0.1 to 1.0 mg/kg), the benzodiazepine partial agonist Ro 17-1812 (0.3 to 3.0mg/kg), and the triazolopyridine CL 218,872 (1.0 to 3.0 mg/kg) substituted consistently for zaleplon in all rats, whereas the imidazo-pyridines zolpidem (3.0 to 10 mg/kg) and alpidem (10 to 30 mg/kg), the benzodiazepine partial agonist bretazenil (0.03 to 10 mg/kg) and the novel putative anxio-lytic CL 273,547 (10 to 56 mg/kg) did not result in consistent drug-appropriate responding in all rats. These results suggest that the effects of zaleplon are similar in many respects to other compounds acting at the benzodiazepine receptor complex but differ as well from both benzodiazepine and non- benzodiazepine drugs. This profile of activity, coupled with additional information in ancillary procedures, yields a pre-clinical profile of a short-acting sedative-hypnotic non-benzodiazepine that is currently in Phase III development for the treatment of sleep disturbances.</p>\\n </div>\",\"PeriodicalId\":94307,\"journal\":{\"name\":\"CNS drug reviews\",\"volume\":\"3 3\",\"pages\":\"207-224\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2006-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1111/j.1527-3458.1997.tb00324.x\",\"citationCount\":\"41\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CNS drug reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.1997.tb00324.x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS drug reviews","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.1997.tb00324.x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 41

摘要

扎来普隆(N-[3-(3-(3-氰吡唑[1,5 -a]嘧啶-7-y 1)苯基)]-N-乙基乙酰胺)是一种非苯二氮卓类镇静催眠药,具有类似苯二氮卓类的镇静作用,但伴随不良副作用的可能性较小。扎来普隆取代大鼠皮层膜上的[3H]氟硝西泮,IC50值为200 nM,并使t-丁基双环硫代酸[35S]TBPS结合率提高73%,表明其药理活性是由GABAA苯二氮卓受体复合物介导的。在各种临床前程序中,如运动活动、肌肉松弛、脑电图、抗惊厥活动和警觉性,扎来普隆产生的效果与其他镇静催眠化合物如三唑仑和氟西泮相似;此外,当评估时,这些作用被苯二氮卓受体拮抗剂氟马西尼逆转。扎来普隆增加松鼠猴和大鼠的惩罚(冲突)反应,氟马西尼也能拮抗这种作用。当以3.0mg/kg的剂量对大鼠进行鉴别刺激时,扎来普隆显示出与训练剂量相关的药物适当性反应增加和反应率相关的降低。三唑仑(0.1至1.0毫克/公斤)苯二氮部分激动剂Ro 17 - 1812(0.3 - 3.0毫克/公斤),和triazolopyridine CL 218872(1.0 - 3.0毫克/公斤)用一贯代替zaleplon老鼠,而imidazo-pyridines唑吡坦(3.0到10毫克/公斤),alpidem(10到30毫克/公斤),苯二氮部分激动剂bretazenil(0.03到10毫克/公斤),这部小说假定的anxio-lytic CL 273547(56 10毫克/公斤)没有在所有老鼠drug-appropriate导致一致的回应。这些结果表明,扎来普隆的作用在许多方面与其他作用于苯二氮卓受体复合物的化合物相似,但也与苯二氮卓和非苯二氮卓药物不同。这种活性特征,加上辅助程序中的附加信息,产生了一种短效镇静催眠非苯二氮卓类药物的临床前特征,该药物目前处于治疗睡眠障碍的III期开发阶段。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A Review of the Preclinical Development of Zaleplon, a Novel Non-Benzodiazepine Hypnotic for the Treatment of Insomnia

Zaleplon (N-[3-(3-cyanopyrazolo[l,5-a]pyrimidin-7-y l)phenyl)]-N-ethylacetamide) is a non-benzodiazepine sedative-hypnotic with benzodiazepine-like sedative effects, but with less apparent liability for accompanying undesirable side effects. Zaleplon displaces [3H]flunitrazepam from rat cortical membranes with an IC50 value of 200 nM and enhances t-butylbicyclophosphorothionate [35S]TBPS binding by 73%, suggesting pharmacological activity mediated by the GABAA benzodiazepine receptor complex. In various preclinical procedures such as motor activity, muscle relaxation, EEG, anticonvulsant activity, and vigilance, zaleplon produced effects similar to those of other sedative-hypnotic compounds such as triazolam and flurazepam; furthermore, these effects, when evaluated, were reversed by the benzodiazepine receptor antagonist flumazenil. Zaleplon increased punished (conflict) responding in squirrel monkeys and rats and these effects were also antagonized by flumazenil. When established as a discriminative stimulus in rats at 3.0mg/kg i.p., zaleplon showed a dose-related increase in drug-appropriate responding up to the training dose and a correlated decrease in response rate. Triazolam (0.1 to 1.0 mg/kg), the benzodiazepine partial agonist Ro 17-1812 (0.3 to 3.0mg/kg), and the triazolopyridine CL 218,872 (1.0 to 3.0 mg/kg) substituted consistently for zaleplon in all rats, whereas the imidazo-pyridines zolpidem (3.0 to 10 mg/kg) and alpidem (10 to 30 mg/kg), the benzodiazepine partial agonist bretazenil (0.03 to 10 mg/kg) and the novel putative anxio-lytic CL 273,547 (10 to 56 mg/kg) did not result in consistent drug-appropriate responding in all rats. These results suggest that the effects of zaleplon are similar in many respects to other compounds acting at the benzodiazepine receptor complex but differ as well from both benzodiazepine and non- benzodiazepine drugs. This profile of activity, coupled with additional information in ancillary procedures, yields a pre-clinical profile of a short-acting sedative-hypnotic non-benzodiazepine that is currently in Phase III development for the treatment of sleep disturbances.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信